Loading...
Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19
Kuo, Tsun-Yung Lin, Meei-Yun Coffman, Robert L. Campbell, John D. Traquina, Paula Lin, Yi-Jiun Liu, Luke Tzu-Chi Cheng, Jinyi Wu, Yu-Chi Wu, Chung-Chin
Kuo, Tsun-Yung
Lin, Meei-Yun
Coffman, Robert L.
Campbell, John D.
Traquina, Paula
Lin, Yi-Jiun
Liu, Luke Tzu-Chi
Cheng, Jinyi
Wu, Yu-Chi
Wu, Chung-Chin
Citations
Altmetric:
Genre
Journal article
Date
2020-11-18
Advisor
Committee member
Group
Department
Subject
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
https://doi.org/10.1038/s41598-020-77077-z
Abstract
The COVID-19 pandemic is a worldwide health emergency which calls for an unprecedented race for vaccines and treatment. In developing a COVID-19 vaccine, we applied technology previously used for MERS-CoV to produce a prefusion-stabilized SARS-CoV-2 spike protein, S-2P. To enhance immunogenicity and mitigate the potential vaccine-induced immunopathology, CpG 1018, a Th1-biasing synthetic toll-like receptor 9 (TLR9) agonist was selected as an adjuvant candidate. S-2P in combination with CpG 1018 and aluminum hydroxide (alum) was found to be the most potent immunogen and induced high titer of neutralizing antibodies in sera of immunized mice against pseudotyped lentivirus reporter or live wild-type SARS-CoV-2. In addition, the antibodies elicited were able to cross-neutralize pseudovirus containing the spike protein of the D614G variant, indicating the potential for broad spectrum protection. A marked Th1 dominant response was noted from cytokines secreted by splenocytes of mice immunized with CpG 1018 and alum. No vaccine-related serious adverse effects were found in the dose-ranging study in rats administered single- or two-dose regimens of S-2P combined with CpG 1018 alone or CpG 1018 with alum. These data support continued development of CHO-derived S-2P formulated with CpG 1018 and alum as a candidate vaccine to prevent COVID-19 disease.
Description
Citation
Kuo, TY., Lin, MY., Coffman, R.L. et al. Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19. Sci Rep 10, 20085 (2020). https://doi.org/10.1038/s41598-020-77077-z
Citation to related work
Springer Science and Business Media LLC
Has part
Scientific Reports, Vol. 10
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu